WeVote
Log In

Bill

Bill

SB 434

AN ACT CONCERNING COMPOUNDING PHARMACIES.

2025 Regular Session Introduced by Saud Anwar

SB 434 establishes regulatory standards for Connecticut compounding pharmacies to improve medication safety and quality control through enhanced licensing and oversight requirements.

REF. TO JOINT COMM. ON General Law
#pharmacies
0
WeVote Research Nonpartisan
Bill Summary · SB 434

Legislative bill overview

SB 434 establishes new regulatory requirements and oversight mechanisms for compounding pharmacies in Connecticut. The bill aims to standardize quality control, licensing, and operational standards for facilities that prepare customized medications for patients.

Why is this important

Compounding pharmacies create personalized medications for patients with specific needs, but without consistent regulation they can pose safety risks through contamination, incorrect dosing, or substandard practices. Strengthening oversight protects vulnerable patient populations—particularly those requiring specialized medications—while maintaining access to compounded drugs that may not be available commercially.

Potential points of contention

  • Compliance costs: Stricter standards and licensing requirements could increase operational expenses, potentially raising medication costs for patients or reducing the number of small compounding operations
  • Scope of regulation: Disagreement over which compounding activities should be regulated most stringently (sterile vs. non-sterile preparations) and how extensively federal FDA standards should be incorporated
  • Access vs. safety balance: Overly restrictive regulations might limit patient access to customized medications, while insufficient regulation leaves room for unsafe practices

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.